|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Cincor Pharma, Inc. (CINC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
43,764,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CinCor Pharma is a biopharmaceutical company focused on developing its primary clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is an oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 inhibits aldosterone synthase activity, providing a differentiated mechanism for lowering aldosterone activity via a reduction of aldosterone synthesis, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. Co. is developing CIN-107 for the indication of chronic kidney disease and primary aldosteronism.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,905,333 |
Total Buy Value |
$0 |
$0 |
$0 |
$57,159,990 |
Total People Bought |
0 |
0 |
0 |
6 |
Total Buy Transactions |
0 |
0 |
0 |
6 |
Total Shares Sold |
0 |
0 |
0 |
6,006 |
Total Sell Value |
$0 |
$0 |
$0 |
$86,011 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
5am Opportunities I (gp), Llc |
10% Owner |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,937,646) |
0 |
|
- |
|
Freeman Mason |
Chief Medical Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(100) |
0 |
|
- |
|
Freeman Mason |
Chief Medical Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(40,000) |
0 |
|
- |
|
Freeman Mason |
Chief Medical Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,494) |
40,000 |
|
- |
|
Sofinnova Venture Partners X, L.p. |
10% Owner |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(6,073,949) |
0 |
|
- |
|
Sofinnova Venture Partners X, L.p. |
10% Owner |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(19,608) |
0 |
|
- |
|
Sofinnova Venture Partners X, L.p. |
10% Owner |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(9,803) |
19,608 |
|
- |
|
Pearce Catherine |
Chief Operating Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,500) |
0 |
|
- |
|
Pearce Catherine |
Chief Operating Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
Pearce Catherine |
Chief Operating Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(140,149) |
15,000 |
|
- |
|
Kalb Michael Wayne |
EVP & Chief Financial Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(202,437) |
0 |
|
- |
|
De Garidel Marc |
Chief Executive Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(200,000) |
0 |
|
- |
|
De Garidel Marc |
Chief Executive Officer |
|
2023-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,500) |
200,000 |
|
- |
|
Pearce Catherine |
Chief Operating Officer |
|
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
155,149 |
|
- |
|
Kalb Michael Wayne |
EVP & Chief Financial Officer |
|
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
177,000 |
202,437 |
|
- |
|
Freeman Mason |
Chief Medical Officer |
|
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
42,500 |
|
- |
|
De Garidel Marc |
Chief Executive Officer |
|
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
212,500 |
|
- |
|
Pearce Catherine |
Chief Operating Officer |
|
2023-01-11 |
4 |
D |
$28.75 |
$114,914 |
D/D |
(3,997) |
140,149 |
|
- |
|
Pearce Catherine |
Chief Operating Officer |
|
2023-01-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,235 |
144,146 |
|
- |
|
Sofinnova Venture Partners X, L.p. |
10% Owner |
|
2022-11-28 |
4 |
S |
$14.32 |
$85,920 |
I/I |
(6,000) |
0 |
|
- |
|
Kalb Michael Wayne |
EVP & Chief Financial Officer |
|
2022-11-04 |
4 |
A |
$0.00 |
$0 |
D/D |
25,437 |
25,437 |
|
- |
|
Sofinnova Capital Ix |
10% Owner |
|
2022-08-15 |
4 |
B |
$30.00 |
$3,999,990 |
I/I |
133,333 |
4,220,979 |
1.5 |
- |
|
5am Opportunities Ii, L.p. |
10% Owner |
|
2022-08-15 |
4 |
B |
$30.00 |
$18,000,000 |
I/I |
600,000 |
487,333 |
1.5 |
- |
|
Healy James |
Director |
|
2022-08-11 |
4 |
B |
$30.00 |
$15,180,000 |
I/I |
506,000 |
6,000 |
2.25 |
- |
|
General Atlantic (spv) Gp, Llc |
10% Owner |
|
2022-08-11 |
4 |
B |
$30.00 |
$2,490,000 |
I/I |
83,000 |
4,209,470 |
1.5 |
- |
|
49 Records found
|
|
Page 1 of 2 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|